Markus P. Vallaster works as Global Medical Head, Oncology Early Development & Hemato-Oncology at Astellas. He oversees the clinical development activities across the Early Oncology portfolio including T cell engagers, immune antibody-drug conjugates (iADCs), and targeted protein degraders, as well as clinical development in Hemato-Oncology. Prior to his joining Astellas, Markus served as Vice President and Head of Clinical Development at a biotechnology company that develops autologous TCR T cell therapies and T cell engagers for patients whose tumors harbor oncogenic driver mutations. He held clinical development roles of increasing responsibility in Immuno-Oncology and Cell Therapies at pharmaceutical companies including AstraZeneca, Takeda, and Boehringer Ingelheim. Markus is a hemato-oncologist with a scientific background in stem cell biology and cell signaling regulation.